Skip to main content

Advertisement

SpringerLink
Log in

The risk stratification in atrial fibrillation

  • SELECTED PAPERS – ATRIAL FIBRILLATION
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is the most common rhythm disorder and represents a major public health problem because it carries an increased risk of arterial thromboembolism and ischemic stroke. Because the absolute benefit of antithrombotic therapy depends on the underlying risk of stroke, an accurate stratification of patients’ risk is needed to choose the appropriate antithrombotic strategy. Over the years, several stroke risk stratification models (RSMs) were developed based on the ‘classic’ risk factors for stroke such as increasing age, hypertension, diabetes mellitus, and left ventricular dysfunction. Among all RSMs, the CHADS2 score is the most popular and used one thanks to its simplicity and endorsement in several widely promulgated practice guidelines. Despite its validation in large datasets and specific population of AF patients, it has many limitations, especially due to the non-inclusion of several proven risk factors for stroke and to the classification of a large number of patients in the intermediate risk category, so creating ambiguity over the most appropriate antithrombotic therapy. Thus, the CHA2DS2-VASc score was introduced and was demonstrated to perform better than the CHADS2, even in a “real world” population of elderly AF patients. Recently, in view of the availability of new oral anticoagulant drugs, that can overcome the limitations of warfarin and allow a more personalized therapy, many efforts are being made to identify other possibilities to assess the thromboembolic risk in AF patients. It has been demonstrated that an increase in C-reactive protein and interleukin-6 and the presence of G20210A factor II gene polymorphism and hyper-homocysteinemia are independent risk factors for ischemic complications in AF patients. Even the presence of chronic renal disease and the daily AF burden, registered with implantable monitors, are associated with an increase risk of stroke. Finally, the assessment of thromboembolic risk should go hand in hand with the consideration of the risk of bleeding. For this purpose, it has been recently developed a practical bleeding risk score, the HAS-BLED, which was included in the last ESC guidelines for the risk stratification of AF patients before starting anticoagulant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hersi A, Wyse DG (2005) Management of atrial fibrillation. Curr Probl Cardiol 30:175–234

    Article  PubMed  CAS  Google Scholar 

  2. Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285:2370–2375

    Article  PubMed  CAS  Google Scholar 

  3. Miyasaka Y, Barnes ME, Gersh BJ et al (2006) Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114:119–125

    Article  PubMed  Google Scholar 

  4. Lip GY, Tse HF, Lane DA (2012) Atrial fibrillation. Lancet 379:648–661

    Article  PubMed  Google Scholar 

  5. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988

    Article  PubMed  CAS  Google Scholar 

  6. Fuster V, Ryden LE, Asinger RW et al (2001) ACC/AHA/ESC Guidelines for the management of patients with Atrial Fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the management of patients with Atrial Fibrillation) developed in collaboration with North American Society of Pacing and Electrophysiology. Eur Heart J 22:1852–1923

    Article  PubMed  CAS  Google Scholar 

  7. Lip GY (2012) Can we predict stroke in atrial fibrillation? Clin Cardiol 35:21–27

    Article  PubMed  Google Scholar 

  8. Gage BF, van Walraven C, Pearce L et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287–2292

    Article  PubMed  CAS  Google Scholar 

  9. Stroke Risk in Atrial Fibrillation Working Group (2008) Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 39:1901–1910

    Article  Google Scholar 

  10. Lip GY, Halperin JL (2010) Improving stroke risk stratification in atrial fibrillation. Am J Med 123:484–488

    Article  PubMed  Google Scholar 

  11. Hughes M, Lip GYH, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care (2008) Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 99:295–304

    PubMed  CAS  Google Scholar 

  12. Hart RG, Pearce LA, Mc Bride R et al (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAFI-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 30:1223–1229

    Article  PubMed  CAS  Google Scholar 

  13. Hart RG, Pearce LA, Rothbart RM et al (2000) Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 35:183–187

    Article  PubMed  CAS  Google Scholar 

  14. Wang TJ, Massaro JM, Levy D et al (2003) A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 290:1049–1056

    Article  Google Scholar 

  15. Van Latum JC, Koudstaal PJ, Venables GS et al (1995) Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with non rheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. Stroke 26:801–806

    Article  PubMed  Google Scholar 

  16. Cabin HS, Clubb KS, Hall C et al (1990) Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 65:1112–1116

    Article  PubMed  CAS  Google Scholar 

  17. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators (1998) Patients with non valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. J Am Geriat Soc 279:1273–1277

    Google Scholar 

  18. Petersen P (1990) Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch Int Med 150:819–821

    Article  CAS  Google Scholar 

  19. Nakagami H, Yamamoto K, Ikeda U et al (1998) Mitral regurgitation reduces the risk of stroke in patients with non rheumatic atrial fibrillation. Am Heart J 136:528–532

    Article  PubMed  CAS  Google Scholar 

  20. Aronow WS, Gutstein H, Hsieh FY (1989) Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol 63:366–367

    Article  PubMed  CAS  Google Scholar 

  21. Aronow WS, Ahn C, Kronzon I (1998) Risk factors for new thromboembolic stroke in patients ≤62 years of age with chronic atrial fibrillation. Am J Cardiol 82:119–121

    Article  PubMed  CAS  Google Scholar 

  22. Fang MC, Go AS, Chang Y, The ATRIA Study Group et al (2008) Comparison of risk stratification schemes to predict thromboembolism in people with non-valvular atrial fibrillation. J Am Coll Cardiol 51:810–815

    Article  PubMed  Google Scholar 

  23. Baruch L, Gage BF, Horrow J et al (2007) Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke 38:2459–2463

    Article  PubMed  CAS  Google Scholar 

  24. van Staa TP, Setakis E, Di Tanna GL et al (2011) A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 9:39–48

    Article  PubMed  Google Scholar 

  25. Lip GYH, Lim HS (2007) Atrial fibrillation and stroke prevention. Lancet Neurol 6:981–993

    Article  PubMed  CAS  Google Scholar 

  26. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457

    Article  Google Scholar 

  27. Stroke Prevention in Atrial Fibrillation Investigators (1995) Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Disord 5:147–157

    Article  Google Scholar 

  28. Stroke Prevention in Atrial Fibrillation investigators (1996) Adjusted dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 348:633–638

    Article  Google Scholar 

  29. Singer DE, Albers G, Dalen J et al (2004) Antithrombotic therapy in atrial fibrillation. The Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy. Chest 126:429–456

    Article  Google Scholar 

  30. National Collaborating Centre for Chronic Conditions Atrial Fibrillation (2006) National Clinical Guideline for Management in Primary and Secondary Care. London Royal College of Physicians

  31. Singer DE, Albers GW, Dalen JE et al (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:546S–592S

    Article  PubMed  CAS  Google Scholar 

  32. Fuster V, Ryden LE, Cannom DS et al (2006) Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27:1979–2030

    Article  PubMed  Google Scholar 

  33. Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 285:2864–2870

    Article  CAS  Google Scholar 

  34. Kim YD, Cha MJ, Kim J et al (2011) Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke 42:930–934

    Article  PubMed  Google Scholar 

  35. Ruiz-Nodar JM, Marín F, Manzano-Fernández S et al (2011) An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. Chest 139:1402–1409

    Article  PubMed  Google Scholar 

  36. Keogh C, Wallace E, Dillon C et al (2011) Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 106:528–538

    Article  PubMed  CAS  Google Scholar 

  37. Karthikeyan G, Eikelboom JW (2010) The CHADS2 score for stroke risk stratification in atrial fibrillation: friend or foe? Thromb Haemost 104:45–48

    Article  PubMed  CAS  Google Scholar 

  38. Lip GY, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272

    Article  PubMed  Google Scholar 

  39. Oelsen JB, Lip GY, Hansen ML et al (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342:124

    Article  Google Scholar 

  40. Olesen JB, Fauchier L, Lane DA et al (2012) Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. Chest 141:147–153

    Article  PubMed  Google Scholar 

  41. Poli D, Antonucci E, Grifoni E et al (2009) Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 101:367–372

    PubMed  CAS  Google Scholar 

  42. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429

    Article  Google Scholar 

  43. Sato H, Ishikawa K, Kitabatake A, Japan Atrial Fibrillation Stroke Trial Group et al (2006) Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 37:447–451

    Article  PubMed  CAS  Google Scholar 

  44. Lip GY, Frison L, Halperin JL et al (2010) Identifying patients at high risk for stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41:2731–2738

    Article  PubMed  CAS  Google Scholar 

  45. Poli D, Lip GYH, Antonucci E et al (2011) Stroke risk stratification in a “real-world” elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 22:25–30

    Article  PubMed  Google Scholar 

  46. You JJ, Singer DE, Howard PA et al (2012) Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based Clinical Practice Guidelines. Chest 141:531–575

    Article  Google Scholar 

  47. Ridker PM, Cushman M, Stampfer MJ et al (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979

    Article  PubMed  CAS  Google Scholar 

  48. Rost NS, Wolf PA, Kase CS et al (2001) Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. Stroke 32:2575–2579

    Article  PubMed  CAS  Google Scholar 

  49. Thambidorai SK, Parakh K, Martin DO et al (2004) Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 94:805–807

    Article  PubMed  CAS  Google Scholar 

  50. Conway DS, Buggins P, Hughes E et al (2004) Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 148:462–466

    Article  PubMed  CAS  Google Scholar 

  51. Pengo V, Filippi B, Biasiolo A et al (2002) Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. Am J Cardiol 90:545–547

    Article  PubMed  CAS  Google Scholar 

  52. Poli D, Antonucci E, Cecchi E et al (2005) Culprit factors for the failure of well conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 36:2159–2163

    Article  PubMed  CAS  Google Scholar 

  53. Glotzer TV, Daoud EG, Wyse DG et al (2009) The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2:474–480

    Article  PubMed  Google Scholar 

  54. Boriani G, Botto GL, Padeletti L et al (2011) Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 42:1768–1770

    Article  PubMed  Google Scholar 

  55. Lee M, Saver JL, Liao HW et al (2010) Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 341:4249

    Article  Google Scholar 

  56. Watanabe H, Watanabe T, Sasaki S et al (2009) Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 158:629–636

    Article  PubMed  Google Scholar 

  57. Garcia DA, Lopes RD, Hylek EM (2010) New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 104:1099–1105

    Article  PubMed  CAS  Google Scholar 

  58. Lip GYH, Andreotti F, Fauchier L et al (2011) Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 13:723–746

    Article  PubMed  Google Scholar 

  59. Lip GY, Zarifis J, Watson RD et al (1996) Physician variation in the management of patients with atrial fibrillation. Heart 75:200–205

    Article  PubMed  CAS  Google Scholar 

  60. Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100

    Article  PubMed  Google Scholar 

  61. Gage BF, Yan Y, Milligan PE et al (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:713–719

    Article  PubMed  Google Scholar 

  62. Holmes DR, Reddy VY, Turi ZG, PROTECT AF Investigators et al (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:534–542

    Article  PubMed  CAS  Google Scholar 

  63. Laupacis A, Albers G, Dalen J et al (1998) Antithrombotic therapy in atrial fibrillation. Chest 114:579–589

    Article  Google Scholar 

  64. Laupacis A, Boysen G, Connolly S et al (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Int Med 154:1449–1457

    Article  Google Scholar 

  65. Lip GY, Lowe GD (1996) ABC of atrial fibrillation. Anti-thrombotic treatment for atrial fibrillation. Br Med J 312:45–49

    Article  CAS  Google Scholar 

  66. Van Walraven C, Hart RG, Wells GA et al (2003) A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Int Med 163:936–943

    Article  Google Scholar 

  67. The Stroke Prevention in Atrial Fibrillation Investigators Predictors of thromboembolism in atrial fibrillation (1992) Predictors of thromboembolism in atrial fibrillation:I. Clinical features of patients at risk. Ann Int Med 116:1–5

    Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy

    Domenico Prisco, Caterina Cenci & Elena Silvestri

  2. SOD Patologia Medica, DAI Biomedicina, AOU Careggi, Largo Brambilla 3, 50134, Florence, Italy

    Domenico Prisco, Elena Silvestri, Giacomo Emmi, Tommaso Barnini & Carlo Tamburini

Authors
  1. Domenico Prisco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caterina Cenci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Silvestri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giacomo Emmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tommaso Barnini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlo Tamburini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Prisco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prisco, D., Cenci, C., Silvestri, E. et al. The risk stratification in atrial fibrillation. Intern Emerg Med 7 (Suppl 3), 233–240 (2012). https://doi.org/10.1007/s11739-012-0805-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-012-0805-x

Keywords

Search

Navigation